Abstract: Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

Abstract: A fusion sequence having a carrier protein which is preferably an E. coli protein having a predicted solubility probability of at least 90% fused to a target heterologous peptide or protein, and a host cell (especially E. coli) transformed with, or having integrated into its genome, a DNA sequence comprising a DNA encoding a carrier protein as defined herein fused to the DNA sequence of a selected heterologous peptide or protein. This fusion sequence is under the control of an expression control sequence capable of directing the expression of a fusion protein in the cell. An objective of the present invention is to improve the purification process of recombinant fusion proteins by avoiding the initial expression of these fusion proteins in E. coli as insoluble inclusion bodies.

Abstract: A fusion sequence having a carrier protein which is preferably an E. coli protein having a predicted solubility probability of at least 90% fused to a target heterologous peptide or protein, and a host cell (especially E. coli) transformed with, or having integrated into its genome, a DNA sequence comprising a DNA encoding a carrier protein as defined herein fused to the DNA sequence of a selected heterologous peptide or protein. This fusion sequence is under the control of an expression control sequence capable of directing the expression of a fusion protein in the cell. An objective of the present invention is to improve the purification process of recombinant fusion proteins by avoiding the initial expression of these fusion proteins in E. coli as insoluble inclusion bodies.

Abstract: A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.

Abstract: A pill press (2), allowing the user to personally press pills (78) of a desired dose, includes a housing (4) having an interior (14) within which a supply of powdered pharmaceutical (36) is contained and a pill cavity form (22) mounted to the housing. Powdered pharmaceutical is transferred to the pill forming cavity (46) of the pill cavity form according to the dose desired. A manually operated pill ram (48) is used to compress the powdered pharmaceutical within pill forming cavity to create the pill. The pill ram is then withdrawn from the pill forming cavity and the pill is automatically ejected from the pill press through a pill outlet (82) formed in the housing by an ejector rod (56).

Abstract: A dairy cow injected with a sustained release formulation comprising bovine somatotropin, a wax, and an oil produces more milk for 28 days.

Abstract: A process for the purification of alcohol oxidase from whole cells of Pichia pastoris grown on methanol by the sequential steps of autolysis, crossflow filtration, ultrafiltration and recrystallization.

Abstract: This invention provides injectable semi-solid formulations comprising a pharmaceutically or veterinary active agent, an oil and a suitable glyceride release modifying agent.

Abstract: A highly efficient process for the precipitation of an amorphous (non-crystalline) aminoglycoside antibiotic salt during the purification process. Illustratively, there are disclosed processes for precipitating gentamicin, neomycin, and sisomicin salts.

Abstract: A chromatographic process for separation of an aminoglycoside antibiotic from impurities. Illustratively, there is disclosed a chromatographic process for separation of the gentamicin complex (C.sub.1, C.sub.2 and C.sub.1a) from impurities. The subject process gives a gentamicin complex recovery of more than double the recovery of the best known prior art gentamicin chromatography process.

Abstract: Acylamino tetrazolyl compounds having anti-allergic activity, methods of making the compounds and pharmaceutical formulations containing the compounds.

Abstract: Acylamino pyrazolyl compounds of the formula: ##STR1## wherein Ar represents an optionally substituted pyrazolyl group, the acylamino group --NR.sup.1 COR.sup.2 being attached to a carbon atom of the pyrazolyl ring, which have anti-allergic activity, methods of making the compounds and pharmaceutical formulations containing the compounds.

Abstract: Oxazoles having a sulfinyl or sulfonyl substituent at the 2-position are provided. Such compounds readily react with an alkali metal salt of a secondary amide in a method of making 2-acylamino oxazole derivatives having anti-allergic activity.